Inhibiting cytokine pathways of myostatin in CKD can mitigate inflammation-associated muscle protein degradation, improve sensitivity to insulin/IGF-1 and reduce muscle protein breakdown, leading to increased muscle growth [71,72]. This evidence concerns the gene MSTN and chronic kidney disease.